Vinorelbine

Vinorelbine, also known by the brand name Navelbine, is a chemotherapy drug that has been tested as a second-line treatment for mesothelioma, both as a single agent and in combination with other drugs such as cisplatin or gemcitabine.

Vinorelbine belongs to a family of chemotherapy drugs known as vinca alkaloids, which were initially created from extracts of the periwinkle plant. The antitumor effects of this drug were discovered in 1959.

Vinorelbine is classified as an antineoplastic agent. It binds to microtubular proteins in cells, which prevents cancer cells from reproducing and leads to their self-destruction.

Vinorelbine Information

  • Other Names: Navelbine, vinorelbine tartrate
  • Manufactured by: Pierre Fabre
  • FDA-approved: Yes (to treat non-small cell lung cancer)
  • Used or Tested in: Breast cancer, cervical cancer, esophageal cancer, Hodgkin’s lymphoma, Kaposi’s sarcoma, mesothelioma, non-small cell lung cancer, ovarian cancer, testicular cancer

Vinorelbine is typically administered in cycles of six weekly intravenous (IV) injections, though this varies based on the patient’s health factors and whether vinorelbine is combined with another chemotherapy drug.

Patients can also take vinorelbine orally in capsule form, but this method usually causes more severe side effects.

Get the Best Treatment

Get help connecting with a top mesothelioma doctor specialized with vinorelbine in mesothelioma treatment.

Get Help Now

Vinorelbine in Mesothelioma Treatment

Vinorelbine regimens are not as effective at extending survival as the standard pemetrexed and cisplatin treatment for mesothelioma. However, because vinorelbine has shown some effectiveness and has relatively low toxicity, doctors have continued to explore its value as a palliative or second-line therapy.

  • Palliative Therapy: Vinorelbine can relieve symptoms and improve quality of life for mesothelioma patients who cannot tolerate other cancer therapies.
  • Second-Line Therapy: Doctors may administer a regimen including vinorelbine to treat cancer reoccurrence after a patient has already received standard chemotherapy.

A 2017 review of second-line chemotherapy treatment for mesothelioma suggests even though international guidelines include vinorelbine as a suggested drug, the research evidence supporting its use is inconclusive.

In 2014, the Wales Cancer Trials Unit began a phase II clinical trial to further study the effectiveness of vinorelbine as a second-line treatment. The researchers also aim to determine whether the BRCA1 gene is required for vinorelbine to cause cancer-cell death.

Side Effects of Vinorelbine

Common side effects include:

  • Low red blood cell counts
  • Low white blood cell counts
  • Nausea and vomiting
  • Muscle weakness
  • Constipation
  • Hair loss
  • Fatigue
  • Mouth sores

Rare side effects include:

  • Pain at the injection site
  • Numbness or tingling in extremities
  • Bruising and bleeding problems
  • Blood in urine
  • Abdominal pain
  • Diarrhea
  • Blood pressure changes

Free VA Claims Assistance

Get Help Now

Qualify for Free Medical Care

See If You Qualify

Get Help Paying for Treatment

Learn More

Daniel King, Content Writer for Asbestos.com

Daniel King joined Asbestos.com in 2017. He comes from a military family and attended high school on a military base. He feels a close connection to veterans, military families and the many hardships they face. As an investigative writer with interests in mesothelioma research and environmental issues, he seeks to educate others about the dangers of asbestos exposure to protect them from the deadly carcinogen linked to asbestos-related conditions. Daniel also holds several certificates in health writing from the Centers for Disease Control and Prevention.

Sources
  1. DrugBank. (2017, November 13). Vinorelbine. Retrieved from https://www.drugbank.ca/drugs/DB00361
  2. Addeo, A., Buffoni, L., and Di Maio, M. (2017, September). Is There Room for Second-Line Treatment of Pleural Malignant Mesothelioma? Retrieved from https://jamanetwork.com/journals/jamaoncology/fullarticle/2598493
  3. OncoLink Team. (2017, August 17). Vinorelbine (Navelbine). Retrieved from https://www.oncolink.org/cancer-treatment/chemotherapy/oncolink-rx/vinorelbine-navelbine-r
  4. ClinicalTrials.gov. (2017, April 11). Vinorelbine in Mesothelioma (VIM). Retrieved from https://clinicaltrials.gov/ct2/show/NCT02139904
  5. Cancer Research UK. (2015, July 24). Vinorelbine (Navelbine). Retrieved from http://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/vinorelbine
  6. Zauderer, M. et al. (2014, June). Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/24690410
  7. Zucali, P. et al. (2014, June). Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Retrieved from http://www.sciencedirect.com/science/article/pii/S0169500213005229
  8. Stebbing, J. et al. (2009, January). The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/18486273
  9. Steele, J. et al. (2000, December). Phase II Study of Vinorelbine in Patients With Malignant Pleural Mesothelioma. Retrieved from http://ascopubs.org/doi/full/10.1200/jco.2000.18.23.3912
  10. Chemocare.com. (n.d.). Vinorelbine. Retrieved from http://chemocare.com/chemotherapy/drug-info/Vinorelbine.aspx

View our resources for patients and families

Get Help Today